Tenofovir is a nucleotide reverse transcriptase inhibitor used in HIV treatment, in PrEP, and for chronic hepatitis B. It comes in two forms that deliver the same active drug in very different ways. Tenofovir disoproxil - the older form, abbreviated TDF - produces higher levels in the bloodstream, which affects the kidneys and bone. Tenofovir alafenamide - TAF - reaches the same concentrations inside cells at a far lower blood level, largely avoiding both. Each has a trade-off, and knowing which you are on is worth doing.
Follow the plan your team gave you. This guide contains no doses.
The kidney effect
Tenofovir disoproxil can cause damage to the proximal tubules of the kidney, and in a small proportion of people a condition called Fanconi syndrome - where the kidney leaks phosphate, glucose and protein.
It is usually reversible on stopping, but can persist if it goes unrecognised.
Kidney function is monitored regularly, along with phosphate and urine protein. A falling eGFR or a falling phosphate are the signals that prompt a switch.
Anti-inflammatory painkillers add substantially to the risk - ibuprofen, naproxen and diclofenac are generally avoided, and paracetamol is the better choice. See naproxen and ibuprofen and medicines that affect your kidneys.
Dehydration during illness raises the risk too - ask about sick day rules if you also take a diuretic, ACE inhibitor or ARB.
The bone effect
Tenofovir disoproxil causes a measurable fall in bone mineral density, most of it in the first year, and has been associated with an increased fracture risk over time.
It matters most in people already at risk - older adults, those on long-term steroids, and postmenopausal women. Adequate calcium and vitamin D, weight-bearing exercise and not smoking all help.
See medicines and bone health and cholecalciferol.
What TAF trades instead
Tenofovir alafenamide is more stable in the blood, so it is delivered into cells largely intact and can be given at a fraction of the dose. Kidney and bone effects are substantially reduced.
The trade-off is metabolic. TAF is associated with greater weight gain and less favourable effects on cholesterol than TDF - a difference that becomes more pronounced in combination with integrase inhibitors.
So neither form is simply better. TDF suits someone worried about weight and lipids with healthy kidneys and bones; TAF suits someone with reduced kidney function or osteoporosis.
See bictegravir and medicines and your weight.
TDF is also considerably cheaper and is available as a generic, which matters for global access more than it does in the UK.
In PrEP
Oral PrEP uses tenofovir disoproxil with emtricitabine. Kidney function is checked before starting and periodically during use.
Event-based dosing is an option for men having anal sex; daily dosing is required for vaginal sex, where protective tissue levels take longer to establish. See emtricitabine and tenofovir.
The hepatitis B warning
Tenofovir is active against hepatitis B, and is in fact a first-line treatment for it.
Someone with chronic hepatitis B taking it for HIV or PrEP has their hepatitis suppressed as well. Stopping suddenly can cause a severe hepatitis flare, which can be dangerous.
Hepatitis B status is checked before starting for exactly this reason, and it is why event-based PrEP dosing is not suitable for people with hepatitis B - the on-off pattern is the problem.
Do not stop tenofovir without specialist advice if you have hepatitis B. See lamivudine.
Side effects
Nausea, diarrhoea, headache and fatigue in the first weeks, often described as start-up symptoms, which usually settle. Taking it with food helps.
Report bone pain, muscle weakness, increased thirst or passing urine more often - these can indicate the kidney tubular problem.
Lactic acidosis and liver problems are rare but recognised with this class - seek advice for deep rapid breathing, severe abdominal pain, unusual tiredness or jaundice.
Interactions
Other nephrotoxic medicines add to kidney risk. Some boosters raise tenofovir levels, which is one reason TAF is preferred in boosted regimens - see cobicistat.
Tell every prescriber you take HIV medication or PrEP, and check anything bought over the counter. St John's wort must be avoided with HIV treatment.
Which one you are on
Combination tablets are known by brand names that do not indicate which form of tenofovir they contain, so people frequently do not know.
It is worth asking, because the answer determines what is being monitored and what the relevant risks are. If your kidney results are drifting, or your weight or cholesterol has changed noticeably, knowing which form you take is the starting point for that conversation - see how medicines get their names.
Switching between the two
Moving from TDF to TAF typically improves kidney markers and bone density, and moving the other way tends to improve lipids and weight.
If kidney results are drifting, or weight has changed markedly since a switch, it is a reasonable thing to raise at review.
Alfuzosin: An Alpha Blocker for Prostate Symptoms covers a related point, and the Conditions section has the rest of these guides.